{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:44:43Z","timestamp":1787676283564,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,12,29]],"date-time":"2007-12-29T00:00:00Z","timestamp":1198886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Community Health"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s10900-007-9083-3","type":"journal-article","created":{"date-parts":[[2007,12,28]],"date-time":"2007-12-28T17:38:54Z","timestamp":1198863534000},"page":"126-133","source":"Crossref","is-referenced-by-count":275,"title":["Limited Uptake of Hepatitis C Treatment Among Injection Drug Users"],"prefix":"10.1007","volume":"33","author":[{"given":"Shruti H.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky L.","family":"Genberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie","family":"Astemborski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kavasery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vlahov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie A.","family":"Strathdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,29]]},"reference":[{"key":"9083_CR1","first-page":"1","volume":"47","author":"Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease","year":"1998","unstructured":"Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. (1998). Centers for disease control and prevention. Morbidity and Mortality Weekly Report, 47, 1\u201339.","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"9083_CR2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","volume":"74","author":"D. L. Thomas","year":"1995","unstructured":"Thomas, D. L., Vlahov, D., Solomon, L., et al. (1995). Correlates of hepatitis C virus infections among injection drug users. Medicine, 74, 212\u2013220.","journal-title":"Medicine"},{"key":"9083_CR3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5694\/j.1326-5377.1990.tb136900.x","volume":"153","author":"J. Bell","year":"1990","unstructured":"Bell, J., Batey, R. G., Farrell, G. C., Crewe, E. B., Cunningham, A. L., & Byth, K. (1990). Hepatitis C virus in intravenous drug users. The Medical Journal of Australia, 153, 274\u2013276.","journal-title":"The Medical Journal of Australia"},{"key":"9083_CR4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00146260","volume":"9","author":"E. J. Ameijden van","year":"1993","unstructured":"van Ameijden, E. J., Van den Hoek, J. A., Mientjes, G. H., & Coutinho, R. A. (1993). A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal of Epidemiology, 9, 255\u2013262.","journal-title":"European Journal of Epidemiology"},{"key":"9083_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2893.2002.00339.x","volume":"9","author":"C. Mathei","year":"2002","unstructured":"Mathei, C., Buntinx, F., & van Damme, D. P. (2002). Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: A systematic review. Journal of Viral Hepatitis, 9, 157\u2013173.","journal-title":"Journal of Viral Hepatitis"},{"key":"9083_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"M. P. Manns","year":"2001","unstructured":"Manns, M. P., McHutchison, J. G., Gordon, S. C., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958\u2013965.","journal-title":"Lancet"},{"key":"9083_CR7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"M. W. Fried","year":"2002","unstructured":"Fried, M. W., Shiffman, M. L., Reddy, K. R., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975\u2013982.","journal-title":"The New England Journal of Medicine"},{"key":"9083_CR8","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1002\/hep.510260701","volume":"26","author":"National Institutes of Health","year":"1997","unstructured":"National Institutes of Health. (1997). Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology, 26, 2S\u201310S.","journal-title":"Hepatology"},{"key":"9083_CR9","first-page":"1","volume":"19","author":"NIH","year":"2002","unstructured":"NIH (2002). Consensus statement on management of hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements, 19, 1\u201346.","journal-title":"NIH Consensus and State-of-the-Science Statements"},{"issue":"Suppl. 1","key":"9083_CR10","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1086\/429501","volume":"41","author":"D. L. Sylvestre","year":"2005","unstructured":"Sylvestre, D. L. (2005). Approaching treatment for hepatitis C virus infection in substance users. Clinical Infectious Diseases, 41(Suppl. 1), S79\u2013S82.","journal-title":"Clinical Infectious Diseases"},{"key":"9083_CR11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","volume":"34","author":"M. Backmund","year":"2001","unstructured":"Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34, 188\u2013193.","journal-title":"Hepatology"},{"key":"9083_CR12","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","volume":"98","author":"D. H. Thiel Van","year":"2003","unstructured":"Van Thiel, D. H., Anantharaju, A., & Creech, S. (2003). Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. The American Journal of Gastroenterology, 98, 2281\u20132288.","journal-title":"The American Journal of Gastroenterology"},{"key":"9083_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","volume":"40","author":"S. Mauss","year":"2004","unstructured":"Mauss, S., Berger, F., Goelz, J., Jacob, B., & Schmutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40, 120\u2013124.","journal-title":"Hepatology"},{"key":"9083_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1086\/344907","volume":"36","author":"C. A. Fleming","year":"2003","unstructured":"Fleming, C. A., Craven, D. E., Thornton, D., Tumilty, S., & Nunes, D. (2003). Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clinical Infectious Diseases, 36, 97\u2013100.","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl. 5","key":"9083_CR15","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/427446","volume":"40","author":"A. Doab","year":"2005","unstructured":"Doab, A., Treloar, C., & Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), S313\u2013S320.","journal-title":"Clinical Infectious Diseases"},{"key":"9083_CR16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2004.07.002","volume":"77","author":"M. A. Stoove","year":"2005","unstructured":"Stoove, M. A., Gifford, S. M., & Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Dependence, 77, 81\u201386.","journal-title":"Drug Alcohol Dependence"},{"key":"9083_CR17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"D. B. Strader","year":"2004","unstructured":"Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147\u20131171.","journal-title":"Hepatology"},{"issue":"Suppl. 3","key":"9083_CR18","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/01.aids.0000192088.72055.90","volume":"19","author":"S. H. Mehta","year":"2005","unstructured":"Mehta, S. H., Thomas, D. L., Sulkowski, M. S., Safaein, M., Vlahov, D., & Strathdee, S. A. (2005). A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV\/HCV-co-infected injection drug users. AIDS, 19(Suppl. 3), S179\u2013S189.","journal-title":"AIDS"},{"key":"9083_CR19","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","volume":"20","author":"S. H. Mehta","year":"2006","unstructured":"Mehta, S. H., Lucas, G. M., Mirel, L. B., et al. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS, 20, 2361\u20132369.","journal-title":"AIDS"},{"key":"9083_CR20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"D. L. Thomas","year":"2000","unstructured":"Thomas, D. L., Astemborski, J., Rai, R. M., et al. (2000). The natural history of hepatitis C virus infection: Host, viral, and environmental factors. The Journal of the American Medical Association, 284, 450\u2013456.","journal-title":"The Journal of the American Medical Association"},{"key":"9083_CR21","first-page":"75","volume":"109","author":"D. Vlahov","year":"1991","unstructured":"Vlahov, D., Anthony, J. C., Munoz, A., et al. (1991). The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants. NIDA Research Monograph, 109, 75\u2013100.","journal-title":"NIDA Research Monograph"},{"key":"9083_CR22","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/JCM.35.12.3274-3277.1997","volume":"35","author":"S. A. Villano","year":"1997","unstructured":"Villano, S. A., Vlahov, D., Nelson, K. E., Lyles, C. M., Cohn, S., & Thomas, D. L. (1997). Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. Journal of Clinical Microbiology, 35, 3274\u20133277.","journal-title":"Journal of Clinical Microbiology"},{"key":"9083_CR23","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","volume":"359","author":"S. H. Mehta","year":"2002","unstructured":"Mehta, S. H., Cox, A., Hoover, D. R., et al. (2002). Protection against persistence of hepatitis C. Lancet, 359, 1478\u20131483.","journal-title":"Lancet"},{"key":"9083_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"R. M. Andersen","year":"1995","unstructured":"Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care: Does it matter? Journal of Health and Social Behavior, 36, 1\u201310.","journal-title":"Journal of Health and Social Behavior"},{"issue":"Suppl. 5","key":"9083_CR25","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1086\/427453","volume":"40","author":"L. E. Taylor","year":"2005","unstructured":"Taylor, L. E. (2005). Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clinical Infectious Diseases, 40(Suppl. 5), S355\u2013S361.","journal-title":"Clinical Infectious Diseases"},{"key":"9083_CR26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.qai.0000131932.21612.49","volume":"37","author":"D. A. Fishbein","year":"2004","unstructured":"Fishbein, D. A., Lo, Y., Reinus, J. F., Gourevitch, M. N., & Klein, R. S. (2004). Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndrome, 37, 1367\u20131375.","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"key":"9083_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","volume":"42","author":"B. Broers","year":"2005","unstructured":"Broers, B., Helbling, B., Francois, A., et al. (2005). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology, 42, 323\u2013328.","journal-title":"Journal of Hepatology"},{"key":"9083_CR28","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","volume":"20","author":"S. H. Mehta","year":"2006","unstructured":"Mehta, S. H., Lucas, G. M., Mirel, L. B., et al. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS, 20, 2361\u20132369.","journal-title":"AIDS"},{"key":"9083_CR29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2893.2005.00548.x","volume":"12","author":"A. Restrepo","year":"2005","unstructured":"Restrepo, A., Johnson, T. C., Widjaja, D., et al. (2005). The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. Journal of Viral Hepatitis, 12, 86\u201390.","journal-title":"Journal of Viral Hepatitis"},{"key":"9083_CR30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","volume":"345","author":"G. L. Davis","year":"2001","unstructured":"Davis, G. L., & Rodrigue, J. R. (2001). Treatment of chronic hepatitis C in active drug users. The New England Journal of Medicine, 345, 215\u2013217.","journal-title":"The New England Journal of Medicine"},{"key":"9083_CR31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","volume":"20","author":"J. A. Morrill","year":"2005","unstructured":"Morrill, J. A., Shrestha, M., & Grant, R. W. (2005). Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine, 20, 754\u2013758.","journal-title":"Journal of General Internal Medicine"},{"issue":"Suppl. 5","key":"9083_CR32","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1086\/427448","volume":"40","author":"G. Matthews","year":"2005","unstructured":"Matthews, G., Kronborg, I. J., & Dore, G. J. (2005). Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), S325\u2013S329.","journal-title":"Clinical Infectious Diseases"},{"key":"9083_CR33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","volume":"351","author":"R. T. Chung","year":"2004","unstructured":"Chung, R. T., Andersen, J., Volberding, P., et al. (2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. The New England Journal of Medicine, 351, 451\u2013459.","journal-title":"The New England Journal of Medicine"},{"key":"9083_CR34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"F. J. Torriani","year":"2004","unstructured":"Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., et al. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 351, 438\u2013450.","journal-title":"The New England Journal of Medicine"},{"key":"9083_CR35","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","volume":"350","author":"A. J. Muir","year":"2004","unstructured":"Muir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in Blacks and non-Hispanic whites. The New England Journal of Medicine, 350, 2265\u20132271.","journal-title":"The New England Journal of Medicine"},{"key":"9083_CR36","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","volume":"39","author":"L. J. Jeffers","year":"2004","unstructured":"Jeffers, L. J., Cassidy, W., Howell, C. D., Hu, S., & Reddy, K. R. (2004). Peginterferon alfa-2a (40\u00a0kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology, 39, 1702\u20131708.","journal-title":"Hepatology"},{"key":"9083_CR37","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2006.06.100","volume":"131","author":"E. J. Lawitz","year":"2006","unstructured":"Lawitz, E. J., Rodriguez-Torres, M., Muir, A., et al. (2006). 28 Days of the hepatitis C protease inhibitor VX-950 in combination with PEG-interferon-ALFA-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology, 131, 950\u2013951.","journal-title":"Gastroenterology"},{"issue":"Suppl. 5","key":"9083_CR38","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","volume":"40","author":"S. A. Strathdee","year":"2005","unstructured":"Strathdee, S. A., Latka, M., Campbell, J., et al. (2005). Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(Suppl. 5), S304\u2013S312.","journal-title":"Clinical Infectious Diseases"},{"key":"9083_CR39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.510290311","volume":"29","author":"S. A. Villano","year":"1999","unstructured":"Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999). Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 29, 908\u2013914.","journal-title":"Hepatology"},{"key":"9083_CR40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1053\/jhep.2002.33151","volume":"35","author":"R. Rai","year":"2002","unstructured":"Rai, R., Wilson, L. E., Astemborski, J., et al. (2002). Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology, 35, 1247\u20131255.","journal-title":"Hepatology"},{"key":"9083_CR41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","volume":"357","author":"F. Imbert-Bismut","year":"2001","unstructured":"Imbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y., & Poynard, T. (2001). Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet, 357, 1069\u20131075.","journal-title":"Lancet"},{"key":"9083_CR42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L. Castera","year":"2005","unstructured":"Castera, L., Vergniol, J., Foucher, J., et al. (2005). Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128, 343\u2013350.","journal-title":"Gastroenterology"},{"key":"9083_CR43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","volume":"29","author":"D. L. Sylvestre","year":"2005","unstructured":"Sylvestre, D. L., Litwin, A. H., Clements, B. J., & Gourevitch, M. N. (2005). The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment, 29, 159\u2013165.","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"Suppl. 3","key":"9083_CR44","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1097\/01.aids.0000192093.46506.e5","volume":"19","author":"T. F. Kresina","year":"2005","unstructured":"Kresina, T. F., Eldred, L., Bruce, R. D., & Francis, H. (2005). Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV\/hepatitis C virus-co-infected patients. AIDS, 19(Suppl. 3), S221\u2013S226.","journal-title":"AIDS"}],"container-title":["Journal of Community Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-007-9083-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10900-007-9083-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-007-9083-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T01:30:03Z","timestamp":1588210203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10900-007-9083-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,29]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["9083"],"URL":"https:\/\/doi.org\/10.1007\/s10900-007-9083-3","relation":{},"ISSN":["0094-5145","1573-3610"],"issn-type":[{"value":"0094-5145","type":"print"},{"value":"1573-3610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,29]]}}}